AI Governance Is Moving From Policy Talk to Bedside Operations
Dylan Reid, president of Dylan Reid Media, framed AI governance as a practical health system problem rather than a branding exercise. As hospitals and payers adopt more automated tools, oversight can no longer sit in a distant committee room while clinicians absorb the consequences at the point of care. The question is not whether healthcare will use AI; it already does. The real issue is how organizations decide when a tool should influence a coverage decision, support a clinical workflow, or stay far away from direct patient care.
Prior authorization sits at the center of that tension. It is one of the most visible places where administrative control, payer policy, clinical judgment and patient frustration collide. When technology is inserted into that process without transparent guardrails, clinicians can lose confidence quickly, especially if automated prompts or denials appear disconnected from the reality of a patient’s condition. In practice, a poorly governed algorithm can behave like a hard stop in the care pathway, delaying imaging, specialty referral, procedures or medication access even when the bedside need is obvious.
A single opaque rule can slow an entire care episode.
Prior Authorization Exposes the Cost of Weak Clinical Alignment
Reid’s comments point to a familiar operational truth: technology only works when it is aligned with the people using it. In healthcare, that means developers, compliance teams, administrators and clinicians have to agree on the purpose of the tool before deployment, not after complaints begin. If prior authorization automation is designed mainly to reduce volume or lower administrative cost, it can easily drift away from clinical nuance. If it is designed with real clinical input, it has a better chance of distinguishing routine requests from medically urgent ones.
That distinction matters because prior authorization touches patients at moments of vulnerability. A delayed approval may mean a postponed scan, a missed therapy window, or a longer period of unmanaged symptoms. The practical burden is also cumulative: every extra call, portal message or documentation chase consumes physician and staff time that could otherwise go to direct care. Governance, then, is not a theoretical layer placed on top of innovation. It is the mechanism that decides whether AI makes care smoother or more brittle.
In that setting, regulatory transparency becomes essential. Hospitals and payers need understandable rules for how AI is trained, where it is used, what data it relies on and who can override it. Clinical teams cannot safely work around systems they do not understand. When an organization cannot explain why a model reached a recommendation, it becomes difficult to defend the recommendation clinically, ethically or legally. Transparency also protects against a quieter failure mode: staff begin to follow the tool reflexively, even when the output no longer matches the patient in front of them.
Why Governance Has to Start Before Deployment
Healthcare leaders often talk about AI as if it were a plug-in feature. Reid’s emphasis on governance suggests the opposite. AI systems need predeployment rules for accountability, clinical escalation, auditability and change management. Those rules should define who owns the model, who monitors drift, who reviews exceptions and how often the system is recalibrated. Without those structures, even a well-intended system can become outdated quickly as guidelines, payer policies and clinical standards shift.
This is especially important in prior authorization because the stakes are not abstract. The process influences when patients receive diagnostics, procedures and treatments. If an automated workflow narrows coverage logic too aggressively, it can magnify existing friction in the system. If it is too permissive, it may fail to control unnecessary utilization. Good governance has to hold both truths at once: the system must protect resources without turning administrative efficiency into clinical delay.
The best guardrail is not just software. It is a governance culture that keeps clinicians inside the decision loop. That may sound basic, but many technology failures begin when the people closest to the patient are asked to adapt after the tool is already live. In a high-acuity environment, small workflow errors can cascade. A missing field, an outdated policy rule or a misread diagnosis code can turn into a denial that reaches the patient as a treatment delay.
Leadership, Culture and the Human Side of Digital Change
Reid also spoke about leadership lessons and culture, and those themes are inseparable from AI adoption. Health systems can buy technology faster than they can earn trust in it. Staff acceptance depends on whether leaders are willing to explain the rationale for change, address concerns honestly and create mechanisms for feedback. If frontline teams believe AI is being used mainly to police them, resistance will be predictable. If they see it as a tool that removes administrative waste while preserving clinical judgment, adoption becomes more plausible.
This is where regulatory transparency overlaps with organizational culture. Clear rules do more than satisfy compliance. They signal respect for the clinicians expected to use the system. They also help patients indirectly, because a transparent process is easier to challenge, correct and improve. In a health system that is increasingly dependent on digital workflows, accountability cannot be an afterthought.
The broader policy implication is straightforward. AI in healthcare will not be judged only by its technical sophistication. It will be judged by whether it supports timely, clinically sound decisions in real-world settings such as prior authorization, scheduling and care coordination. Those are the moments where automated systems can either reduce friction or harden it. The difference rests on governance, not rhetoric.
Hospitals and payers now face a basic test: can they deploy AI without eroding the clinical reasoning that medicine depends on? The answer will hinge on transparent rules, meaningful clinician input and a willingness to revisit the system when it stops matching the bedside reality it was meant to serve.